Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
BBIO - BridgeBio Pharma, Inc.
Market Cap 5.14B P/E - EPS this Y 53.70% Ern Qtrly Grth -
Income -453.82M Forward P/E -11.81 EPS next Y -60.70% 50D Avg Chg 56.00%
Sales 219.12M PEG -0.51 EPS past 5Y - 200D Avg Chg 133.00%
Dividend N/A Price/Book N/A EPS next 5Y 26.80% 52W High Chg -12.00%
Recommedations 1.90 Quick Ratio 3.34 Shares Outstanding 188.03M 52W Low Chg 382.00%
Insider Own 5.43% ROA -48.44% Shares Float 127.53M Beta 1.08
Inst Own 93.06% ROE - Shares Shorted/Prior 19.61M/18.02M Price 32.00
Gross Margin 98.91% Profit Margin -207.11% Avg. Volume 3,084,340 Target Price 48.46
Oper. Margin -7,963.47% Earnings Date Oct 31 Volume 2,656,761 Change -6.62%
Healthcare | Biotechnology | United States
About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma, Inc. News
10/04/24 3 Top Stocks That Could Still Rocket Higher in 2024
10/03/24 BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
10/01/24 5 FDA decisions to watch in the fourth quarter
09/30/24 BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
09/30/24 BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
09/27/24 BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
09/17/24 BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
09/12/24 The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly
09/11/24 BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition
09/11/24 BridgeBio trims gene therapy budget after seeing data on adrenal gland medicine
09/10/24 BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
09/10/24 BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
09/06/24 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
08/30/24 Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug
08/30/24 Why Is BridgeBio Pharma Stock Trading Higher On Friday?
08/30/24 BridgeBio Pharma Reports Positive Additional Data From Phase 3 Study of Acoramidis; Shares Rise
08/30/24 BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
08/29/24 BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
08/28/24 BridgeBio Pharma to Participate in September Investor Events
08/26/24 BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence
BBIO Chatroom

User Image Papermoon347 Posted - 33 minutes ago

$BBIO Might see $28 this week unless market sells off badly .

User Image IN0V8 Posted - 10 hours ago

$BBIO Opportunity Leerink Partners cuts target price to $47 from $48

User Image Papermoon347 Posted - 1 day ago

$BBIO This stock was and is deeply undervalued!

User Image Mimiboy Posted - 2 days ago

$BBIO

User Image Irish_lass Posted - 3 days ago

$BBIO

User Image Capitulation_0 Posted - 3 days ago

$BBIO continuation! I'm speechless!

User Image J3DI Posted - 4 days ago

$BBIO Scam pos clown company....no one need this crap....shit loser stonk

User Image J3DI Posted - 4 days ago

$BBIO best short entry Point... RIP Hard criminal FRAUDs

User Image J3DI Posted - 4 days ago

$BBIO and RIP Hard criminal FRAUDs

User Image Pika_Capital Posted - 4 days ago

$BBIO same message applies here still

User Image Capitulation_0 Posted - 4 days ago

$BBIO so today.. no worries on adcom. some discussion on whether ALNY drug will be covered as combo.

User Image J3DI Posted - 4 days ago

$BBIO Delisting safe $APLS

User Image J3DI Posted - 4 days ago

$BBIO Zero incoming 😎🤣.... Clown company

User Image J3DI Posted - 5 days ago

$BBIO criminal company succccer fraud bullshit SCAM.... short this trash

User Image JoeTheCheap Posted - 5 days ago

$BBIO WOW Cathy! Thanks for the recommendation! Unless you’ve sold, you’re really hurting now!

User Image J3DI Posted - 5 days ago

$BBIO More Short here.... RIP Hard

User Image J3DI Posted - 5 days ago

$BBIO short this criminal SCAM

User Image Irish_lass Posted - 5 days ago

$BBIO 👀

User Image buyandsold Posted - 5 days ago

$BBIO this price action is bannanas

User Image J3DI Posted - 5 days ago

$BBIO what a scam

User Image MikeyNJ Posted - 6 days ago

$BBIO I concur that an Adcom is highly unlikely. The comparative data of Acoramidis to Vutisiran and Tafamidis is very convincing. Analysts remain extremely bullish with an average target of $48.50 and a Street high of $70. Oppenheimer is an outlier who last week put out a cautious research report although they maintain their Street low target of $37. The price action after ALNY released the results of their Helios-B trial was extremely positive confirming the safety and efficacy of Acoramidis. The KKR sale of 5.8 million shares took the air out of the balloon. They continue to remain the largest holder of BBIO with approximately 25 million shares. I think there remains an overhang following this transaction as KKR signed a 60 day lockup where they agreed they will not sell any more shares. There always remains the uncertainty that when the lockup period expires they could sell more. In my opinion, that is creating a buying opportunity as the data is compelling.

User Image Capitulation_0 Posted - 6 days ago

$BBIO SLNO no Adcom up 10%... It's PUDFA one month further out than BBIO.

User Image Capitulation_0 Posted - 6 days ago

$BBIO No adcom for SLNO.. up 9% was up a lot more. Will this move on no adcom news? I think it's pretty safe to say no adcom at this point. SLNO PUDFA is end of Dec. BBIO is end of Nov.

User Image J3DI Posted - 1 week ago

$BBIO succccer fuccer company Fraud Scam pos clown scamer

User Image LoneBroker Posted - 1 week ago

$BBIO 📈🥳

User Image LoneBroker Posted - 1 week ago

$BBIO I think I saw a cat 📈🥳

User Image SorosSonosSatoshi Posted - 1 week ago

$BBIO $ALLK AND now 0.444?

User Image Article_AI Posted - 1 week ago

$BBIO 3 Top Stocks That Could Still Rocket Higher in 2024 Upcoming Food and Drug Administration decisions could push these stocks through the roof. https://www.stck.pro/news/BBIO/90614996/

User Image uyenng25_ Posted - 1 week ago

$BBIO good above $24 for a swing, PTs 27, 32

User Image paaps Posted - 1 week ago

$BBIO Vol starting to pick up, def should see a bump late afternoon

Analyst Ratings
HC Wainwright & Co. Buy Oct 2, 24
HC Wainwright & Co. Buy Sep 30, 24
HC Wainwright & Co. Buy Sep 17, 24
Cantor Fitzgerald Overweight Sep 16, 24
HC Wainwright & Co. Buy Sep 16, 24
B of A Securities Buy Sep 11, 24
Cantor Fitzgerald Overweight Sep 9, 24
Piper Sandler Overweight Sep 4, 24
HC Wainwright & Co. Buy Sep 3, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
MCCORMICK FRANK Director Director Dec 26 Sell 42.06 100,000 4,206,000 627,689 12/28/23
VIKING GLOBAL INVESTORS LP 10% Owner 10% Owner Jul 18 Sell 35 1,500,000 52,500,000 25,120,991 07/19/23
STEPHENSON BRIAN C Secretary, Treasurer.. Secretary, Treasurer & CFO Apr 05 Sell 15.454 55,500 857,697 101,337 04/07/23
Kumar Neil CEO and President CEO and President Apr 05 Sell 15.4638 120,000 1,855,656 1,132,722 04/07/23
STEPHENSON BRIAN C Secretary, Treasurer.. Secretary, Treasurer & CFO Mar 03 Sell 10.9607 62,692 687,148 156,837 03/03/23
Kumar Neil CEO and President CEO and President Mar 03 Sell 10.9602 120,000 1,315,224 1,252,722 03/03/23
STEPHENSON BRIAN C Secretary, Treasurer.. Secretary, Treasurer & CFO Feb 16 Sell 12.86 17,717 227,841 219,529 02/21/23
Kumar Neil CEO and President CEO and President Feb 16 Sell 12.7 44,798 568,935 4,813,197 02/21/23
STEPHENSON BRIAN C Secretary, Treasurer.. Secretary, Treasurer & CFO Feb 03 Sell 11.0079 61,040 671,922 219,184 02/06/23
Kumar Neil CEO and President CEO and President Feb 03 Sell 11.0058 120,000 1,320,696 1,372,722 02/06/23
STEPHENSON BRIAN C Secretary, Treasurer.. Secretary, Treasurer & CFO Jan 05 Sell 7.6748 61,040 468,470 280,224 01/06/23
Kumar Neil CEO and President CEO and President Jan 05 Sell 7.6738 120,000 920,856 1,492,722 01/06/23
Ellis Andrea Director Director Mar 15 Buy 8.39 12,000 100,680 12,000 03/17/22
DANIELS RONALD J Director Director Dec 28 Buy 13.54 22,147 299,870 10,402 12/30/21
DANIELS RONALD J Director Director Dec 28 Sell 12.8 11,745 150,336 12/30/21
STEPHENSON BRIAN C See Remarks See Remarks Feb 18 Buy 62.5 8,000 500,000 300,043 02/18/21
Turtle Cameron See Remarks See Remarks Dec 29 Sell 69.64 19,500 1,357,980 12,568 12/29/20
Turtle Cameron See Remarks See Remarks Dec 29 Option 5.83 19,500 113,685 32,068 12/29/20
SCHELLER RICHARD H See Remarks See Remarks Dec 23 Sell 65.14 60,401 3,934,521 45,860 12/23/20
Turtle Cameron See Remarks See Remarks Nov 25 Option 17 5,000 85,000 13,310 11/25/20
Turtle Cameron See Remarks See Remarks Nov 25 Sell 47.12 5,000 235,600 12,568 11/25/20
HENDERSON MICHAEL THOMAS Chief Business Offic.. Chief Business Officer Nov 18 Option 1.05 10,000 10,500 277,751 11/18/20
HENDERSON MICHAEL THOMAS Chief Business Offic.. Chief Business Officer Nov 18 Sell 45 10,000 450,000 267,751 11/18/20
HOMCY CHARLES J Chairman of Pharmace.. Chairman of Pharmaceuticals Oct 19 Option 17 10,256 174,352 1,214,023 10/19/20
HOMCY CHARLES J Chairman of Pharmace.. Chairman of Pharmaceuticals Oct 19 Sell 41 10,256 420,496 1,203,767 10/19/20
Turtle Cameron See Remarks See Remarks Oct 02 Option 5.83 14,500 84,535 27,068 10/02/20
Turtle Cameron See Remarks See Remarks Oct 02 Sell 37.92 14,500 549,840 12,568 10/02/20
HOMCY CHARLES J Chairman of Pharmace.. Chairman of Pharmaceuticals Sep 29 Sell 37.22 99,257 3,694,346 1,203,767 09/29/20
Turtle Cameron See Remarks See Remarks Sep 22 Option 17 2,500 42,500 15,068 09/22/20
Turtle Cameron See Remarks See Remarks Sep 22 Sell 42.01 2,500 105,025 12,568 09/22/20
HENDERSON MICHAEL THOMAS Chief Business Offic.. Chief Business Officer Sep 22 Option 0.22 10,000 2,200 277,751 09/22/20
HENDERSON MICHAEL THOMAS Chief Business Offic.. Chief Business Officer Sep 22 Sell 40 10,000 400,000 267,751 09/22/20
Turtle Cameron See Remarks See Remarks Sep 16 Option 17 2,500 42,500 15,068 09/16/20
Turtle Cameron See Remarks See Remarks Sep 16 Sell 37.06 2,500 92,650 12,568 09/16/20